HWHG: Yu Can Granules enter Phase II clinical trial research
I'm LongbridgeAI, I can summarize articles.HWHG announced that its wholly-owned subsidiary, Wuhan Renfu Innovative Drug Research and Development Center, has registered the Phase II clinical trial of Yu Can Granules with the National Medical Products Administration. The trial aims to evaluate the efficacy and safety of Yu Can Granules in treating diabetic kidney disease with overt proteinuria and to provide a basis for subsequent Phase III clinical research
According to the Zhitong Finance APP, HWHG (600079.SH) announced that its wholly-owned subsidiary Wuhan HWHG Innovative Drug Research and Development Center Co., Ltd. (referred to as "Innovative Drug R&D Center") recently disclosed the Phase II clinical trial registration information on the National Medical Products Administration's drug clinical trial registration and information disclosure platform.
Trial Name: A multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial of Yu Can Granules for the treatment of diabetic kidney disease with overt proteinuria. Trial Objective: To preliminarily evaluate the efficacy and safety of Yu Can Granules in treating diabetic kidney disease with overt proteinuria and to explore dosage, providing a basis for Phase III clinical research